NCT02645149 2026-02-27
Match Mel
Melanoma Institute Australia
Phase 2 Completed
Clinical Trials
24 trialsNCT03745794 2025-12-23
Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03075423 2025-09-26
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
Goethe University
Phase 2 Completed
NCT03217071 2024-10-23
Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer
University of California, San Francisco
Phase 2 Completed
NCT04205955 2024-05-01
Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer Survivors
SWOG Cancer Research Network
Phase 2 Completed
NCT05045443 2024-01-08
CurcumPedALL
Ain Shams University
Phase 2 Completed
NCT04496219 2024-01-02
Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT03390595 2023-10-18
INDUCOMAIN
Associació per a la Recerca Oncologica, Spain
Phase 2 Completed
NCT02101385 2023-09-28
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT02784288 2023-06-27
Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03469284 2023-04-25
MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03472274 2023-04-13
DUTRENEO
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 2 Completed
NCT04733833 2023-02-01
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
Vascular Biogenics Ltd. operating as VBL Therapeutics
Phase 2 Completed
NCT04333914 2022-09-30
IMMUNONCOVID
Centre Leon Berard
Phase 2 Completed
NCT02107937 2022-05-04
Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Completed
NCT03329690 2022-03-18
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]
Daiichi Sankyo
Phase 2 Completed
NCT01883362 2021-03-17
RADIUS
Novartis
Phase 2 Completed
NCT02187302 2020-05-28
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
Phase 2 Completed
NCT03472053 2020-05-19
A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer
BioMarck Pharmaceuticals, Ltd.
Phase 2 Completed
NCT01529411 2019-04-04
MAJA
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT02200081 2018-11-15
IMPULSE
Mologen AG
Phase 2 Completed
NCT02107950 2018-08-15
Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Completed
NCT01360840 2015-12-14
PERSEUS
EMD Serono
Phase 2 Completed
NCT00084123 2009-07-10
Healing Touch and Relaxation Therapies in Cervical Cancer Patients
National Center for Complementary and Integrative Health (NCCIH)
Phase 2 Completed